Clinical Trials Logo

Abortion Early clinical trials

View clinical trials related to Abortion Early.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05342974 Active, not recruiting - Abortion Early Clinical Trials

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

Start date: April 19, 2022
Phase: Early Phase 1
Study type: Interventional

Medication abortion is a way of ending a pregnancy using pills. The current FDA-approved regimen for medication abortion uses mifepristone and misoprostol. This study is testing whether a different medication, atorvastatin, followed by misoprostol, can be used to end a pregnancy. Participants at 35-49 days of pregnancy will receive an oral dose of atorvastatin (80 mg) to swallow at the clinic as well as taking atorvastatin (80 mg) daily for six additional days, with a return to clinic on day 8 after initial visit to take a dose of misoprostol (800 mcg). Additionally, follow-up visits will occur on approximately days 3, 8 and 11 for a clinician to perform an ultrasound to see if the abortion is complete.

NCT ID: NCT05278780 Active, not recruiting - Abortion Early Clinical Trials

Medication Abortion With Autonomous Self-Assessment Project

MA-ASAP
Start date: June 1, 2022
Phase: N/A
Study type: Interventional

In this study, the investigators propose to create and pilot-test an asynchronous medication abortion provision service.

NCT ID: NCT03736681 Active, not recruiting - Clinical trials for Abortion in First Trimester

Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage

Start date: October 29, 2018
Phase: Phase 1
Study type: Interventional

The investigators are conducting a study on pain control for dilation and curettage (D&C). Participants are eligible to enroll if they are a planning to have a D&C in a participating clinic. The investigators are studying how different ratios of medication to liquid affect pain when injected around the cervix. Both potential methods use the same dose of medication, though researchers would like to know which one works better. To be in this study, participants must be over the age of 18 with an early pregnancy loss or undesired pregnancy measuring less than 12 weeks gestation undergoing D&C while awake in clinic.